Metastatic Merkel Cell Carcinoma

Also known as: Metastatic Merkel Cell Carcinoma (MCC)

DrugDrug NameDrug Description
DB11945AvelumabAn anti-PD-L1 monoclonal antibody used to treat metastatic merkel cell carcinoma, metastatic urothelial carcinoma, or renal cell carcinoma.
DB09037PembrolizumabA PD-1 blocking antibody used to treat various types of cancer, including metastatic melanoma, non small-cell lung cancer, cervical cancer, head and neck cancer, and Hodgkin's lymphoma.
DrugDrug NamePhaseStatusCount
DB14681Cortisone1Active Not Recruiting1
DB00531Cyclophosphamide1Recruiting1
DB06186Ipilimumab1Active Not Recruiting1
DB00959Methylprednisolone1Active Not Recruiting1
DB09035Nivolumab1Active Not Recruiting1
DB09037Pembrolizumab1Recruiting1
DB00635Prednisone1Active Not Recruiting1
DB00020Sargramostim1Recruiting1
DB00864Tacrolimus1Active Not Recruiting1
DB11945Avelumab1 / 2Recruiting1
DB14681Cortisone1 / 2Recruiting1
DB06186Ipilimumab1 / 2Recruiting1
DB00959Methylprednisolone1 / 2Recruiting1
DB09035Nivolumab1 / 2Recruiting1
DB00635Prednisone1 / 2Recruiting1
DB00877Sirolimus1 / 2Recruiting1
DB11945Avelumab2Recruiting1
DB09037Pembrolizumab2Active Not Recruiting1
DB15766Retifanlimab2Active Not Recruiting1
DB11945AvelumabNot AvailableApproved for Marketing1